Studies on Anticancer activity of novel transition metal arene complexes invitro and invivo

Abstract

Cancer becomes one of the leading causes of morbidity and mortality worldwide and according to World Health Organization (WHO) it will be an alarming situation by 2020. Different approaches have been used to treat cancer but for advanced stages of cancer, effective therapeutic regimen is very essential to be developed. However, continuous efforts are going on to develop new anticancer drugs with novel mechanisms of action to cure the malignancy and also to conquer the side effects and limitations of existing drugs. The discovery of anticancer activity of cisplatin stimulated the research in the area of metal-based antitumor drugs worldwide. In recent years, several other metals (non-platinum) complexes have been extensively investigated for their antitumor activity and it has been observed that the derivatives of ruthenium, rhodium and iridium may develop as possible anticancer chemotherapeutics. Two ruthenium drugs, NAMIand#8208;A and KP1019 are currently in clinical trials. NAMIand#8208;A is an arene Ru drug and antitumor metastatic inhibitor in nature. KP-1019 is activated through hypoxic environment and both drugs described above are well tolerated by patients. Studies on Ru, Rh and Ir complexes offer development of new anticancer chemotherapeutic regimens and also display the selective capabilities without systemic toxicity. On the basis of these facts it worthy to undertake this investigation on anticancer activity of novel Ru, Rh and Ir arene complexes (20 complexes of three different series) and following objectives were being made: newline newlineObjectives 1. Evaluation of cytotoxicity and antiproliferation activity of arene complexes in vitro and in vivo. 2. Detection of apoptotic induction and effect on cell cycle phase distribution. 3. To determine the possible molecular mechanism of anticancer activity of arene complexes. newline